FLT3 and acute myeloid leukemia: Activating mutations of FMS-like tyrosine kinase 3 (FLT3) account for approximately 30% of acute myeloid leukemia (AML) patients and can be either FLT3 internal tandem duplication (FLT3-ITD) mutations or FLT3 tyrosine kinase domain point mutations (FLT3-TKD) .1 In addition, mutation of FLT3-ITD occurs in 25% of diagnosed AML patients and which are associated with poor outcomes [1, 2].